List of Nucynta drug patents
Nucynta is owned by Collegium Pharm Inc.
Nucynta contains Tapentadol Hydrochloride.
Nucynta has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nucynta are:
- USRE39593
Nucynta was authorised for market use on 15 October, 2012.
Nucynta is available in solution;oral dosage forms.
Nucynta can be used as relief of moderate to severe acute pain.
The generics of Nucynta are possible to be released after 27 June, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(7 months ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(2 years from now) | |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2012
Treatment: Relief of moderate to severe acute pain
Dosage: SOLUTION;ORAL
NUCYNTA family patents
15
United States
3
Norway
3
European Union
2
Portugal
2
Germany
2
Spain
2
Brazil
2
Argentina
2
Austria
2
Cyprus
2
Slovenia
2
Poland
2
Denmark
1
Russia
1
Croatia
1
New Zealand
1
Mexico
1
Peru
1
China
1
Korea, Republic of
1
South Africa
1
Canada
1
Japan
1
Israel
1
Australia
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic